The sex-shift in single disease and multimorbid asthma and rhinitis during puberty

Theresa Keller, MSc1 C Hohmann, MSc1, M Standl, PhD2, AH Wijga, PhD3, U Gehring, PhD4, E Melén, MD5,6, C Almqvist, MD5,7, S Lau, MD8, E Eller, PhD9, U Wahn, MD8, E Soegaard Christiansen MD9,22, A v. Berg, MD10, J Heinrich, MD11,12, I Lehmann, PhD12, D Maier, PhD13, DS Postma, MD15, JM Antó, MD16,19,20,21, J Bousquet, MD16,17, T Keil, MD,1* S Roll, PhD1*
Corresponding author: Theresa Keller, MSc
Institute of Social Medicine, Epidemiology and Health Economics,
Charité – Universitätsmedizin Berlin
Luisenstraße 57,
10117 Berlin, Germany
E-Mail: theresa.keller@charite.de

Short title: The sex-shift in allergic diseases during puberty

This article is protected by copyright. All rights reserved.
Keywords: Asthma, Allergic Multimorbidity, Birth Cohort, Puberty, Rhinitis

Abstract

Background. Cross-sectional studies suggested that allergy prevalence in childhood is higher in boys compared to girls, but it remains unclear if this inequality changes after puberty. We examined the sex-specific prevalence of asthma and rhinitis as single and as multimorbid diseases before and after puberty-onset in longitudinal cohort data.

Methods. In six European population-based birth cohort studies we assessed the outcomes current rhinitis, current asthma, current allergic multimorbidity (i.e. concurrent asthma and rhinitis), puberty status, and allergic sensitization by specific serum antibodies (immunoglobulin E) against aero-allergens. With generalized estimating equations we analysed the effects of sex, age, puberty (yes/no), and possible confounders on the prevalence of asthma and rhinitis, and allergic multimorbidity in each cohort separately and performed individual participant data meta-analysis.

Findings. We included data from 19,013 participants from birth to age 14-20 years. Current rhinitis only affected girls less often than boys before and after puberty onset: adjusted odds ratio for females vs. males 0.79 (95%-confidence interval 0.73-0.86) and 0.86 (0.79-0.94) respectively (sex-puberty interaction p= 0.089).

Similarly, for current asthma only, females were less often affected than boys both before and after puberty-onset: 0.71, 0.63-0.81 and 0.81, 0.64-1.02, respectively (sex-puberty interaction p=0.327).

The prevalence of allergic multimorbidity showed the strongest sex-effect before puberty onset (female-male-OR 0.55, 0.46-0.64) and a considerable shift towards a sex-balanced prevalence after puberty onset (0.89, 0.74-1.04); sex-puberty interaction: p<0.001.

Interpretation. The male predominance in prevalence before puberty and the ‘sex-shift’ towards females after puberty-onset was strongest in multimorbid patients who had asthma and rhinitis concurrently.
1 INTRODUCTION

The prevalence of two of the most common chronic diseases globally, asthma and rhinitis, remains at a high level or is still increasing in some parts of the world.(1-3) At around puberty, considerable sex-specific differences in the prevalence of allergic diseases have been identified.(4-6) For asthma, the prevalence is higher in boys than in girls before puberty, but after puberty there is a female predominance persisting in adulthood.(7-10)

In rhinitis, sex-specific prevalence differences before and after puberty onset are less clear.(11) A recent meta-analysis of cross-sectional population-based studies suggested a ‘sex-switch’ around puberty from male to female predominance in rhinitis prevalence.(12) However, longitudinal sex-specific evaluations from early childhood to adolescence regarding rhinitis as well as asthma prevalence are lacking. Long-term birth cohort studies are essential to understanding the life course and childhood predictors of allergies including sex-specific differences.(13) Since the statistical power of individual cohorts is often insufficient to allow stratified analyses,(14) the European Commission funded MeDALL (Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015) with the aim to integrate 14 European birth cohorts including 44,010 participants for combined and harmonised analyses.(15)

This large dataset allowed examining a potential sex-shift in the prevalence of less common but more severe allergic phenotypes such as multimorbidity of asthma and rhinitis and their association with and without allergen-specific immunoglobulin E (IgE) antibodies with the sufficient statistical power.(15)

Asthma and rhinitis are both heterogeneous diseases with many forms and phenotypes of different aetiologies, thus we differentiated between asthma only and rhinitis only as single entities and multimorbidity.(16, 17)

In the present analyses, we aimed to examine and compare a possible ‘sex-shift’ in prevalence of asthma, rhinitis and multimorbidity (asthma and concurrent rhinitis) during puberty using the pooled MeDALL cohort data.
2 METHODS

Study design, setting and included birth cohorts

The present study is based on the six older population-based birth cohorts from the MeDALL project. (16, 18) We chose the following inclusion criteria: (1) at least one prospective assessment of asthma and rhinitis before puberty (i.e. from birth to 10 years of age) and after possible puberty onset (11-18 years); (2) at least one assessment of allergic sensitization based on specific antibodies against aero-allergens in serum; (3) at least one prospective assessment of the puberty status at 10 years or older. The included birth cohorts were PIAMA (The Netherlands), BAMSE (Sweden), DARC (Denmark), and MAS, GINIplus and LISAplus (all Germany). All participating birth cohorts had obtained ethical approval from their local review boards. Recruitment, study design and data collection for the birth cohort studies have been described in detail previously. (19-23)

Information on health outcomes and puberty status has been collected at several time points. The number of time points and exact ages of the participants at follow-up differed between cohorts. When combining the cohorts, we had data for a total of 14 possible follow up time points (Table S1 in supplemental material).

A panel of experts within the MeDALL consortium followed a stringent process (24) for data harmonization between the participating cohorts. For each variable to be harmonized a reference definition was agreed and each cohort then evaluated how their own cohort definition matched the reference definition as complete, partial or impossible. All single evaluations were then reviewed in a joint workshop to create the final harmonized dataset.

Outcome variables

Primary Outcomes

We defined three primary outcome measures: current asthma only, current rhinitis only, and current allergic multimorbidity.

Current asthma only
‘Current asthma only’ was defined as a positive answer to at least two of the three following questions:

- “Has your child ever been diagnosed by a doctor as having asthma?”
- “Has your child (Have you) taken any medication for asthma (including inhalers, nebulizers, tablets or liquid medicines) or breathing difficulties (chest tightness, shortness of breath) in the last 12 months?”
- “Has your child (Have you) had wheezing or whistling in your chest at any time in the last 12 months?” (25)

and a negative ‘current rhinitis’ status. If two of these three questions were answered with ‘no’ at the respective follow-up, asthma status was negative.

Current rhinitis only

The occurrence of ‘current rhinitis only’ at the respective follow-up assessment was defined by a positive (parent or self-reported) answer to the question ‘Has your child had/Did you have problems with sneezing, or a runny, or blocked nose when s/he/you did not have a cold or flu in the past 12 months?’ (yes/no) based on the International Study of Asthma and Allergy in Childhood (ISAAC)(25) and a negative current asthma status. A negative answer to the question above defined a negative current rhinitis status.

Current Allergic Multimorbidity

A positive ‘current allergic multimorbidity’ status was defined as concurrent asthma and rhinitis. If either rhinitis or asthma was negative, allergic multimorbidity status was defined as negative.

Secondary Outcomes

To investigate possible effects of puberty status on allergic sensitization, we included the following six secondary outcomes:

- ‘IgE-associated current rhinitis’
- ‘Non IgE-associated current rhinitis’
- ‘IgE-associated current asthma’
- ‘Non IgE-associated current asthma’
- ‘IgE-associated current allergic multimorbidity (asthma and rhinitis)’
- ‘Non IgE-associated current allergic multimorbidity (asthma and rhinitis)’

A positive allergic sensitization status was defined as specific immunoglobulin E (IgE) ≥ 0.35 kU/L in serum against at least one common aero-allergen (dog, cat, house dust mite, or birch pollen; since they were assessed in all included cohorts) at the same follow-up at which the clinical phenotypes were assessed or, if serum samples were missing, at the preceding follow-up. A negative allergic sensitization status was defined as s-IgE < 0.35 kU/L against all four common aero-allergens.

As a sensitivity analysis we defined the six secondary outcomes including sensitization status based on IgE against food and aero-allergens, defined as s-IgE ≥ 0.35 kU/L against at least one common food (cow’s milk, hen’s egg, peanut) or aero-allergen. A negative allergic sensitization status was defined as s-IgE < 0.35 kU/L against all of the seven allergens.

**Definition of main exposure variable puberty**

Puberty categories were defined using the Puberty Development Scales (PDS). (26, 27) For boys, the following items were included: (1) body hair growth, (2) voice change, and (3) facial hair growth. For girls, the Puberty Category Scores (PCS) was based on (1) body hair growth, (2) breast development, and (3) menstruation.

*For each item (except menstruation) four response categories indicate the extent of puberty from “not yet started” up to “seems complete”. These were coded with values of 1 to 4 and summed up for each participant. According to these sum scores (and the stage of menstruation in girls) PCS was defined as Prepubertal, Early Pubertal, Midpubertal, Late Pubertal, Postpubertal. For the final binary analysis variable ‘puberty’ Midpubertal, Late Pubertal, and Postpubertal were considered as a positive puberty status. Additionally, to gain more insight into possible effects of the age at puberty-onset in relation to the sex-shift of allergic diseases during puberty, we conducted a sensitivity analysis including the information of the time point of puberty-onset by using the age
period 10-12 years for early and 13-16 years for late puberty-onset. Definition of possible confounders

Based on results from previous studies we considered the following variables in the analyses as possible confounders: age (categorical (for all cohort specific models except for MAS) or continuous (for models in the MAS cohort and in pooled dataset) - depending on number of available follow-ups per cohort), history of parental allergies (yes = at least one parent with asthma and/or rhinitis diagnosis / no = two non-allergic parents), and maternal smoking during pregnancy (yes/no).(28, 29)

Statistical methods

For categorical variables, absolute and relative frequencies are presented. Results of all descriptive analyses are presented separately by cohort and pooled for all cohorts and sex. We pooled relative frequencies using random effect meta-analyses.

We used generalized estimating equations (GEE) to estimate adjusted Odds Ratios (OR) and 95% confidence interval (CI) for the associations of the primary and secondary outcome variables with sex and puberty (and the interaction thereof) adjusting for the possible confounders described above, and age as the longitudinal time variable. The focus was on the interaction of puberty and sex as an indicator of sex-specific changes in outcome prevalence before versus after puberty onset. With GEE models outcomes and exposure of the participants are analysed over time, taking the longitudinal design and thus the repeated measurements of one individual, which are not independent of each other, into account.

Initially, we pooled the harmonized cohort datasets to perform a one-stage Individual Participant Data (IPD) meta-analysis.(30) We used the GEE-model described above on the combined dataset of all cohorts with a birth cohort identifier variable included as an additional covariable in the model with participants nested in cohorts to account for the clustering in each cohort.

Additionally, as a comparative sensitivity analysis, we conducted a two-stage IPD meta-analysis, which consisted of the estimation of the adjusted odds ratios with the GEE-model described above for each cohort separately as first stage and a subsequent random-effect meta-analyses with the inverse-
variance method combining as second stage the adjusted effect estimates from all cohorts.

Heterogeneity across the studies was assessed using the chi-squared Q-statistic and $I^2$.(31)

All our analyses are of explorative nature and we did not adjust for multiple testing. Missing values were not imputed. Thus the number of included participants varied for more complex analyses including several variables and different number of missings per variable. We performed the meta-analyses in R version 3.1.2 (R Foundation for Statistical Computing) and all other analyses with SAS version 9.4 (SAS Institute, Cary, NC, USA).

3 RESULTS

Description of cohorts
We included six birth cohorts with a total of 19,013 recruited participants: PIAMA (the Netherlands, 1996, n = 3,963), BAMSE (Sweden, 1994, n = 4,089), DARC (Denmark, 1998, n=562), and three German birth cohorts (GINIplus, 1995, n = 5,991; LISAplus, 1997, n = 3,094; and MAS, 1990, n=1,314). We used data from birth to age 14 - 20 years (depending on the cohort). The number of observations used varied over follow-up time points due to drop-outs and non-response. For analyses concerning the three GEE models for the primary outcomes, all necessary information (at least at one time point) was available for 14,533 participants.

Puberty and exposure variables
In total, approximately 50% of the participants were female. Puberty started earlier in girls than in boys (e.g. 62% vs 3% at age 11 in PIAMA, the Netherlands) with boys catching up in later teenage years (across the cohorts, except DARC), about 90-99% of the participants had reached puberty according to our definition at the last included follow-up. Exposures such as self-reported parental allergies (ever) and maternal smoking differed slightly between the cohorts, but not considerably between boys and girls (Table 1).
**Prevalence of primary outcomes**

**Current rhinitis only**

Prevalence of current rhinitis only (i.e. without coexisting asthma) varied between the cohorts. Among boys, it was generally higher than girls in earlier childhood, but this difference became smaller with increasing age (Figure 1 and Supplement Table 1).

**Current asthma only**

Prevalence of current asthma only differed slightly between the cohorts, with the highest prevalence in BAMSE across the follow-ups. At a younger age, more boys than girls had asthma but in teenage years these differences were smaller or even disappeared such as in GINIplus and BAMSE (Figure 2 and Supplement Table 2).

**Allergic multimorbidity**

Current allergic multimorbidity prevalence was higher among boys than girls especially in earlier childhood. These differences decreased as the participants grew older to smaller or even no differences between males and females (Figure 3 and Supplement Table 3).

**Primary outcomes in relation to puberty**

**Current rhinitis only**

For current rhinitis only, the male predominance before puberty remained, but was less pronounced after the onset of puberty. There was some degree of heterogeneity among the cohorts after puberty-onset ($P=39.6\%$) but not before puberty (Table 2). The pooled one stage IPD meta-analysis also indicated this trend towards a female-male-ratio decline (interaction sex*puberty-onset $p=0.089$) (Figure 4).

**Current asthma only**

For current asthma only, we found a male predominance before puberty that decreased slightly after puberty-onset. There was no heterogeneity among the cohorts (Table 2, Figure 4).
Allergic Multimorbidity

The strongest male predominance before puberty was found for allergic multimorbidity (OR: 0.55, 95%-CI 0.46-0.64). Furthermore, this outcome showed a clear shift towards a sex-balanced prevalence after puberty-onset (0.89, 0.74-1.07); sex-puberty-onset interaction term p < 0.001 (Figure 4). There was no considerable heterogeneity among the cohorts (Table 2).

Sensitivity analyses: two-stage IPD meta-analyses

The additional two stage IPD meta-analyses, which we performed as a sensitivity analyses, showed similar effect estimates for all three primary outcomes as the pooled one stage IPD approach. The two-stage approach also allowed us to calculate I² for the assessment of potential heterogeneity between the cohorts. There was no considerable statistical heterogeneity for the primary outcomes apart from current rhinitis only with some moderate heterogeneity (Table 2).

Sensitivity analyses: differentiating early and late puberty-onset

Differentiating between early (age 10-12 years) and late puberty-onset (age 13-16 years) did not change the effect estimates and the corresponding p-values for the interaction “pubertytime*sex” considerably compared to our primary analyses (Supplement Table S5).

IgE- and non-IgE-associated outcomes

IgE- and non-IgE-associated current rhinitis only and current asthma only

Prevalence estimates of IgE-associated current rhinitis only and asthma only were higher in male than in female participants before and to a lesser extent after puberty-onset.

In contrast, both non-IgE-associated rhinitis only and asthma only showed sex-balanced prevalence estimates before puberty and a slight female predominance in the prevalence after puberty-onset; corresponding sex-puberty interaction terms p=0.074 and p=0.141, respectively (Table 2).

IgE- and non-IgE-associated allergic multimorbidity

For IgE-associated allergic multimorbidity, we found a sex-shift from a strong male predominance before puberty towards a sex-balanced prevalence after puberty-onset (sex-puberty interaction term p<0.001). Similarly, non-IgE-associated allergic multimorbidity showed also a sex-shift in the prevalence from a clear male predominance before puberty towards a sex-balanced occurrence of this phenotype after puberty-onset (Table 2).

This article is protected by copyright. All rights reserved.
Sensitivity analyses: allergic sensitization including IgE against aero- and food allergens

Including IgE against the common aero- and food allergens showed similar effect estimates for IgE- and non-IgE-associated current rhinitis only, current asthma only and allergic multimorbidity compared to our primary definition of allergic sensitization status based only on common aero-allergens (Table S6).

4 DISCUSSION

Key results

Our individual participant data meta-analyses of six large European birth cohorts showed a strong male predominance before puberty for the prevalence of current allergic multimorbidity and to a lesser extent for current rhinitis and current asthma as single entities. After puberty-onset the sex-specific odds ratio shifted towards females in all phenotypes resulting in a rather sex-balanced prevalence for asthma only and particularly for allergic multimorbidity.

Considering allergic sensitization status, we found that for IgE-associated rhinitis only and asthma only the clear male predominance decreased slightly, but remained significant after puberty-onset, whereas for IgE-associated multimorbidity we found a much stronger shift towards females with rather sex-balanced prevalence after puberty-onset.

The non-IgE-associated (single and multimorbid) phenotypes showed a slight female predominance after puberty-onset, which was strongest for non-IgE-associated rhinitis.

Strengths and limitations

Based on validated puberty assessments this is the first longitudinal evaluation of birth cohort data assessing the sex-shift in prevalence at around puberty not only for rhinitis or asthma as single entities, but also for allergic multimorbidity. We combined prospectively collected data from six European birth cohorts from early childhood through adolescence up to age 20. For the IPD meta-analysis we used pooled raw original data, which allowed us to define outcome and exposure variables, confounding variables and interactions consistently across the cohorts. Previous sex-shift
evaluations had almost exclusively cross-sectional designs and used heterogeneous methods. This limited the comparability of sex-ratios before and after puberty-onset between these studies, because the participants were not the same in the two groups (i.e. before and after puberty). Due to the longitudinal character of the data in our study with homogeneous prospective assessments, comparability of sex-specific prevalence estimates before and after puberty-onset can be considered more robust. Our findings gained external validity from the combination of several large cohorts showing similar results in different European regions and recruitment settings.

One limitation of (birth) cohort studies is that they are dynamic and prone to missing values during the course of repeated follow-up assessments as some participants, in particular teenagers drop-out or participate irregularly. This may cause selection bias and potentially limits the representativeness of the results.

Furthermore, at the time of the last follow up included in our present analyses, some participants (PIAMA, the Netherlands, and DARC, Denmark) were just 14 years old and may not have reached puberty. The proportion of girls not in puberty was 0.2% (PIAMA) and 4.1% (DARC), which was comparable to the other cohorts with older participants at last follow-up, and for boys approximately 35% (DARC) and 15% (PIAMA). We cannot rule out a potential bias, especially if single cohorts will be analysed separately, but consider this risk of bias negligible in our large meta-analyses, where the absolute number of prepubertal participants at the last follow-up was comparatively small (e.g. DARC represented <3% of all children recruited for the 6 birth cohorts in total). We aimed to examine possible effects of the age at which puberty started by defining two main categories of early (age 10-12 years) and late onset (age 13-16 years) based on the assessment time points of the cohorts. We did not find a considerable impact of the timing of puberty with this approach. To analyse this aspect in more detail than in our sensitivity analysis was not possible because the cohorts differed in terms of the ages and follow-up intervals at which pubertal stage was assessed.
Comparison to other studies

Pinart et al. found a sex-switch for current (allergic) rhinitis prevalence from male to female predominance in their recent meta-analysis of published cross-sectional studies comparing childhood populations with adolescent and adulthood populations including mainly middle-aged participants. Participants of all birth cohorts included in our IPD meta-analyses except one had not reached adulthood yet. Therefore, we may have only found an indication towards a sex-shift but not a complete ‘sex-switch’ in the prevalence of rhinitis as Pinart et al.’s analyses suggested. However, our findings point towards such an effect. Pinart et al.’s study differed further from ours since their meta-analyses focused on cross-sectional studies that mostly did not measure IgE-sensitization, thus could not distinguish between IgE-associated and non-IgE-associated rhinitis phenotypes.(32, 33) Furthermore, the differentiation between rhinitis as a single or as part of a multimorbid phenotype was not made by Pinart et al. either.(12)

In the Isle-of-Wight birth cohort study from the UK, which started in 1989, prevalence of sensitized and non-sensitized rhinitis in childhood and early adulthood showed a similar pattern to our findings. Concerning the differences in sensitization status of rhinitis patients, they showed a male predominance in rhinitis during early childhood as well as at 18 years of age only in subjects with rhinitis who were sensitized. For non-sensitized rhinitis, females in the UK cohort had a significantly higher prevalence at age 18 years.(34) Our results showed sex-balanced prevalence both before and after puberty-onset in teenage adolescents who were on average slightly younger. The theory that allergic sensitization might play a crucial role in the natural history of rhinitis can be reaffirmed considering sex-differences.(35)

For asthma prevalence, several mostly cross-sectional evaluations showed a sex-switch from childhood to adolescence towards a female predominance.(5, 7) We could not confirm a complete prevalence sex-shift for asthma prevalence, but a rather sex-balanced prevalence for asthma only after puberty. However, our statistical power was decreased when examining asthma without coexisting rhinitis and stratifying it by sensitized and non-sensitized subtypes. Therefore, we were not able to determine more precisely sex-specific prevalence differences in these strata. The TRAILS study from
the Netherlands found a sex-shift between 11 and 16 years, but no association with pubertal stages as an explanation for the shift was found.(36) Other than in our study, they investigated asthma regardless of the presence of rhinitis which may explain the different findings.

Due to the common coexistence of asthma and rhinitis (37) we aimed at evaluating sex-specific prevalence patterns in multimorbid patients to reduce the knowledge gap for these more severely affected patients. In particular, population-based research on sex-specific prevalence differences among multimorbid patients is scarce. The few earlier evaluations such as in the MAS(38) and BAMSE(39) cohorts showed an increasing prevalence of allergic multimorbidity with age. BAMSE found a male predominance in the prevalence of multimorbidity until the age of 12 that was confirmed by our analyses of multiple European cohorts. Regardless of allergic sensitization status, we found a stronger male predominance in the prevalence of allergic multimorbidity before puberty-onset than for the single entities. In puberty, this clear sex-specific prevalence predominance decreased and shifted clearly towards a sex-balanced prevalence of multimorbidity after puberty-onset. Based on the difference between prevalence in both individual morbidities and in multimorbidity we hypothesize that this is not an additive effect but that due to the double burden different mechanisms may play a role.

**Potential mechanisms**

Physiological changes during puberty such as endogenous (40) or exogenous sexual hormones (birth control pills) (41) have been proposed as potential determinants. Possible explanations include anatomical differences,(42) differences in the immune response profile such as increased IgE levels and enhanced cytokine responses in boys compared to girls in early childhood,(42, 43) whereas in puberty and adulthood female sex steroids are in general associated with enhanced immune responses and testosterone with dampening inflammatory responses.(44)

Sociocultural factors such as different symptom reporting behaviour between men and women(42) have been suggested as mechanisms behind the gender shift in allergic diseases. These are less of a concern in childhood since symptoms were parent-reported but may play a role from school-age on as teenagers fill-out their own study questionnaires.

This article is protected by copyright. All rights reserved.
Conclusions

In conclusion, we found the strongest male predominance before puberty for the prevalence of current allergic multimorbidity and also, but less pronounced, for current rhinitis and current asthma as single entities. With increasing age, we saw a ‘sex-shift’ towards females resulting in a rather sex-balanced prevalence after puberty-onset. This effect was much stronger in multimorbid children who had both current rhinitis and coexisting asthma than in those with rhinitis or asthma alone. We observed a larger prevalence-shift towards females in non-sensitized than sensitized subjects.

Further cohort follow-up assessments are required to examine the hypothesised prevalence sex-switch to a female predominance regarding the different allergic phenotypes in adulthood.

AUTHOR CONTRIBUTIONS

TKeller wrote the initial draft under supervision of SR and TKeil. TKeller developed the statistical analysis plan, conducted and interpreted the statistical analyses with supervision of SR. CH, TKeil, JMA and JB coordinated the harmonized follow-up assessment of all birth cohorts including the development of a common standardized questionnaire at age 14-20 and participated in the development of the statistical analysis plan, MS, AvB (GINIplus), JH, IL (LISAplus), UG, AW (PIAMA), EM, CA (BAMSE), SL, TKeil, UW (MAS), EE, ESC (DARC) coordinated the local follow-up assessments, and provided the newly as well as all the relevant previously collected birth cohort data. DM coordinated the harmonization of all previously collected data for the integration in a new common birth cohort database, provided harmonized datasets and participated in the coordination of the follow-up assessment. All authors read the different versions of the manuscript, provided comments, participated in the critical revision of the manuscript and the interpretation of the results, and approved the final version.

CONFLICT OF INTEREST STATEMENT

EM reports non-financial support from Thermo Fisher Scientific during the conduct of the study. The University of Groningen has received money for DSP regarding a grant for research from Astra Zeneca, Chiesi, Genentec, GSK and Roche. Fees for consultancies were given to the University of Groningen by Astra Zeneca, Boehringer Ingelheim, Chiesi, GSK, Takeda and TEVA.

This article is protected by copyright. All rights reserved.
JB reports personal fees from Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, personal fees from Almirall, AstraZeneca, Chiesi, GSK, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva, Uriach, personal fees from null, outside the submitted work.
SL reports grants and personal fees from Symbiopharm, grants from Allergopharma/Merck, outside the submitted work.
TKeil and DM report grants from European Commission, during the conduct of the study.
TKeller, SR, CH, UG, AW, MS, AvB, CA, UW, EE, ESC, IL, JH and JMA declare no competing interests.

ACKNOWLEDGEMENTS

PIAMA:
We thank all the children and their parents for participating in the study. Furthermore, we gratefully acknowledge the contributions of Marjan Tewis to the data management of the PIAMA study.

BAMSE:
We would like to thank all participating children and their families in the BAMSE study. BAMSE was supported by the Swedish Research Council, FORMAS, the Swedish Heart-Lung Foundation, the Stockholm County Council (ALF), and the SFO (Strategic Research Area) Epidemiology Program at Karolinska Institutet. Thermo Fisher Scientific kindly provided the ImmunoCAP reagents for IgE analyses in BAMSE, but had no role in study design, data analysis, or preparation of the manuscript.

GINIplus:
The authors thank all the families for their participation in the GINIplus study. Furthermore, we thank all members of the GINIplus Study Group for their excellent work. The GINIplus Study group consists of the following: Institute of Epidemiology I, Helmholtz Zentrum München, German Research Center for Environmental Health, Neuherberg (Heinrich J, Brüske I, Schulz H, Flexeder C, Zeller C, Standl M, Schnappinger M, Ferland M, Thiering E, Tiesler C); Department of Pediatrics, Marien-Hospital, Wesel (Berdel D, von Berg A); Ludwig-Maximilians-University of Munich, Dr von Hauner Children’s Hospital (Koletzko S); Child and Adolescent Medicine, University Hospital rechts der Isar of the Technical University Munich (Bauer CP, Hoffmann U); IUF-Environmental Health Research Institute, Düsseldorf (Schikowski T, Link E, Klümper C).

LISAplus:
The authors thank all the families for their participation in the LISAplus study. Furthermore, we thank all members of the LISAplus Study Group for their excellent work. The LISAplus Study group consists of the following: Helmholtz Zentrum München, German Research Center for Environmental Health, Institute of Epidemiology I, Munich (Heinrich J, Schnappinger M, Brüske I, Ferland M, Lohr W, Schulz H, Zeller C, Standl M); Department of Pediatrics, Munich Municipal Hospital “St. Georg”, Leipzig (Borte M, Gnodtke E); Marien Hospital Wesel, Department of Pediatrics, Wesel (von Berg A, Berdel D, Stiers G, Maas B); Pediatric Practice, Bad Honnef (SchAAF B); Helmholtz Centre of Environmental Research – UFZ, Department of Environmental Immunology/Core Facility Studies, Leipzig (Lehmann I, Bauer M, Röder S, Schilde M, Nowak M, Herberth G, Müller J, Hain A); Technical University Munich, Department of Pediatrics, Munich (Hoffmann U, Paschke M, Marra S); Clinical Research Group Molecular Dermatology, Department of Dermatology and Allergy, Technische Universitität München (TUM), Munich (Ollert M).

DARC:
The DARC cohort would like to acknowledge the Danish Allergy Research Council and Prof. Carsten

This article is protected by copyright. All rights reserved.
Bindslev-Jensen, Prof. Klaus Ejner Andersen, Prof. Susanne Halken, Prof. Arne Høst and Prof. Lars K. Poulsen for initiating the DARC cohort, and follow-up investigators MD. Lene Annette Norberg, MD Hanne Jöhnke, MD Morten Østerballe, MD Henrik Fomsgards Kjaer, Prof. Charlotte G. Mortz as well as nurses/Lab. Technicians for performing and collecting data through all follow-ups. Finally we would like to thank all children in the cohort and their families for participation during the past 9 follow-ups.

MAS:
We thank all families who participated since 1990 in some or all MAS follow-up assessments. We also like to thank our many collaborators, especially M Götz, P Fiedler, J Kuehr, MV Kopp, J Forster (Freiburg); A Schuster, M Wisbauer, V Wahn (Düsseldorf); O Nitsche, A Heß, W Dorsch, W Kamin, F Zepp (Mainz); M Paschke, U Hoffmann, CP Bauer (Munich); P Wagner, B Niggemann, C Grüber, W Luck, A Dannemann, R Krüger, G Schulz, J Beschorner, G Edenharter, Y Lee-Hübner, P Matricardi, M Kulig, L Grabenhenrich, A Reich, and C Sommerfeld (Berlin).

FUNDING
This work was supported by MeDALL, a collaborative project conducted within the European Union under the Health Cooperation Work Programme of the 7th Framework Programme [grant agreement No. 261357].

The PIAMA study is supported by The Netherlands Organization for Health Research and Development; The Netherlands Organization for Scientific Research; The Netherlands Asthma Fund (grant 4.1.14.001); The Netherlands Ministry of Spatial Planning, Housing, and the Environment; and The Netherlands Ministry of Health, Welfare, and Sport.

The BAMSE study was supported by The Swedish Research Council, The Swedish Heart and Lung Foundation, The Swedish Research Council for Working Life and Social Welfare, the Swedish Asthma and Allergy Association Research Foundation, The Swedish Research Council Formas, Stockholm County Council (ALF), and the European Commission’s Seventh Framework Program MeDALL under grant agreement No. 261357.

The GINIplus study was mainly supported for the first 3 years of the Federal Ministry for Education, Science, Research and Technology (interventional arm) and Helmholtz Zentrum Munich (former GSF) (observational arm). The 4 year, 6 year, 10 year and 15 year follow-up examinations of the GINIplus study were covered from the respective budgets of the 5 study centres (Helmholtz Zentrum Munich (former GSF), Research Institute at Marien-Hospital Wesel, LMU Munich, TU Munich and from 6 years onwards also from IUF - Leibniz Research-Institute for Environmental Medicine at the University of Düsseldorf) and a grant from the Federal Ministry for Environment (IUF Düsseldorf, FKZ 20462296). Further, the 15 year follow-up examination of the GINIplus study was supported by the Commission of the European Communities, the 7th Framework Program: MeDALL project, and by the companies Mead Johnson and Nestlé.

The LISAplus study was mainly supported by grants from the Federal Ministry for Education, Science, Research and Technology and in addition from Helmholtz Zentrum Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef for the first 2 years. The 4 year, 6 year, 10 year and 15 year follow-up examinations of the LISAplus study were covered from the respective budgets of the

This article is protected by copyright. All rights reserved.
involved partners (Helmholtz Zentrum Munich (former GSF), Helmholtz Centre for Environmental Research - UFZ, Leipzig, Research Institute at Marien-Hospital Wesel, Pediatric Practice, Bad Honnef, IUF – Leibniz-Research Institute for Environmental Medicine at the University of Düsseldorf) and in addition by a grant from the Federal Ministry for Environment (IUF Düsseldorf, FKZ 20462296). Further, the 15 year follow-up examination of the LISAplus study was supported by the Commission of the European Communities, the 7th Framework Program: MeDALL project.

DARC was funded by the Danish Allergy Research Counsel and received additional support from the Danish Ministry of Food, Agriculture and Fisheries (FOESIO-OUH-9), the University of Southern Denmark, Odense University Hospital, Region of Southern Denmark, Thermo Fisher Scientific, Sweden, ALK-Abelló, Denmark, and The John and Birthe Meyer Foundation.

The MAS study was funded by grants from the German Federal Ministry of Education and Research (BMBF; reference numbers 07015633, 07 ALE 27, 01EE9405/5, 01EE9406) and the German Research Foundation (DFG; reference number KE 1462/2-1).

5 LITERATURE

1. Aït-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J, et al. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009;64(1):123-148.
2. Meltzer EO, Blaiss MS, Derebery MJ, Mahr TA, Gordon BR, Sheth KK, et al. Burden of allergic rhinitis: results from the Pediatric Allergies in America survey. Journal of Allergy and Clinical Immunology 2009;124(3):S43-S70.
3. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med 2006;355(21):2226-2235.
4. Venn A, Lewis S, Cooper M, Hill J, Britton J. Questionnaire study of effect of sex and age on the prevalence of wheeze and asthma in adolescence. Bmj 1998;316(7149):1945-1946.
5. Tollefsen E, Langhammer A, Romundstad P, Bjørner L, Johnsen R, Holmen TL. Female gender is associated with higher incidence and more stable respiratory symptoms during adolescence. Research Medicine 2007;101(5):896-902.
6. Yao T-C, Ou L-S, Yeh K-W, Lee W-I, Chen L-C, Huang J-L. Associations of Age, Gender, and BMI with Prevalence of Allergic Diseases in Children: PATCH Study. Journal of Asthma 2011;48(5):503-510.
7. Almqvist C, Worm M, Leynaert B. Impact of gender on asthma in childhood and adolescence: a GA2LEN review. Allergy 2008;63(1):47-57.
8. Postma DS. Gender Differences in Asthma Development and Progression. Gender Medicine 2007;4, Supplement 2:S133-S146.
9. Mandhane PJ, Greene JM, Cowan JO, Taylor DR, Sears MR. Sex differences in factors associated with childhood-and adolescent-onset wheeze. American journal of respiratory and critical care medicine 2005;172(1):45-54.
10. Protudjer JL, Lundholm C, Bergstrom A, Kull I, Almqvist C. Puberty and asthma in a cohort of Swedish children. Ann Allergy Asthma Immunol 2014;112(1):78-79.
11. Robertson CF, Dalton MF, Peat JK, Haby MM, Bauman A, Kennedy JD, et al. Asthma and other atopic diseases in Australian children. Med J Aust 1998;168(9):434-438.

This article is protected by copyright. All rights reserved.
12. Pinart M, Keller T, Reich A, Frohlich M, Cabieses B, Hohmann C, et al. Sex-Related Allergic Rhinitis Prevalence Switch from Childhood to Adulthood: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol 2017;172(4):224-235.

13. Bousquet J, Anto J, Sunyer J, Nieuwenhuijsen M, Vrijheid M, Keil T, et al. Pooling birth cohorts in allergy and asthma: European Union-funded initiatives - a MeDALL, CHICOS, ENRIECO, and GA(2)LEN joint paper. Int Arch Allergy Immunol 2013;161(1):1-10.

14. Bousquet J, Gern JE, Martinez FD, Anto JM, Johnson CC, Holt PG, et al. Birth cohorts in asthma and allergic diseases: report of a NIAID/NHLBI/MeDALL joint workshop. J Allergy Clin Immunol 2014;133(6):1535-1546.

15. Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy 2011;66(5):596-604.

16. Bousquet J, Anto J, Auffray C, Akdis M, Cambon-Thomsen A, Keil T, et al. MeDALL (Mechanisms of the Development of ALLergy): an integrated approach from phenotypes to systems medicine. Allergy 2011;66(5):596-604.

17. Ballardini N, Bergstrom A, Wahlgren CF, van Hage M, Hallner E, Kull I, et al. IgE antibodies in relation to prevalence and multimorbidity of eczema, asthma and rhinitis from birth to adolescence. Allergy 2015.

18. Bousquet J, Anto JM, Akdis M, Auffray C, Keil T, Monas I, et al. Paving the way of systems biology and precision medicine in allergic diseases: the MeDALL success story: Mechanisms of the Development of ALLergy; EU FP7-CP-IP; Project No: 261357; 2010-2015. Allergy 2016;71(11):1513-1525.

19. Bergmann RL, Bergmann KE, Lau-Schadensdorf S, Luck W, Dannemann A, Bauer CP, et al. Atopic diseases in infancy. The German multicenter atopy study (MAS-90). Pediatr Allergy Immunol 1994;5(6 Suppl):19-25.

20. Berg A, Kramer U, Link E, Bollrath C, Heinrich J, Brockow I, et al. Impact of early feeding on childhood eczema: development after nutritional intervention compared with the natural course - the GINIplus study up to the age of 6 years. Clin Exp Allergy 2010;40(4):627-636.

21. Zutavern A, Brockow I, Schaaf B, von Berg A, Diez U, Borte M, et al. Timing of solid food introduction in relation to eczema, asthma, allergic rhinitis, and food and inhalant sensitization at the age of 6 years: results from the prospective birth cohort study LISA. Pediatrics 2008;121(1):e44-52.

22. Wickman M, Kull I, Pershagen G, Nordvall SL. The BAMSE project: presentation of a prospective longitudinal birth cohort study. Pediatr Allergy Immunol 2002;13 Suppl 15:11-13.

23. Wijga AH, Kerkhof M, Gehring U, de Jongste JC, Postma DS, Aalberse RC, et al. Cohort profile: the prevention and incidence of asthma and mite allergy (PIAMA) birth cohort. Int J Epidemiol 2014;43(2):527-535.

24. Fortier I, Burton PR, Robson PJ, Ferretti V, Little J, L’Heureux F, et al. Quality, quantity and harmony: the DataSHaPER approach to integrating data across bioclinical studies. Int J Epidemiol 2010;39(5):1383-1393.

25. Asher M, Keil U, Anderson H, Beasley R, Crane J, Martinez F, et al. International Study of Asthma and Allergies in Childhood (ISAAC): rationale and methods. European respiratory journal 1995;8(3):483-491.

26. Petersen AC, Crockett L, Richards M, Boxer A. A self-report measure of pubertal status: Reliability, validity, and initial norms. J Youth Adolesc 1988;17(2):117-133.

27. Carskadon MA, Acebo C. A self-administered rating scale for pubertal development. Journal of Adolescent Health 1993;14(3):190-195.

This article is protected by copyright. All rights reserved.
28. Neuman A, Hohmann C, Orsini N, Pershagen G, Eller E, Kjaer HF, et al. Maternal smoking in pregnancy and asthma in preschool children: a pooled analysis of eight birth cohorts. *Am J Respir Crit Care Med* 2012;186(10):1037-1043.

29. Vardavas CI, Hohmann C, Patelarou E, Martinez D, Henderson AJ, Granell R, et al. The independent role of prenatal and postnatal exposure to active and passive smoking on the development of early wheeze in children. *Eur Respir J* 2016;48(1):115-124.

30. Debray TP, Moons KG, Abo-Zaied GMA, Koffijberg H, Riley RD. Individual participant data meta-analysis for a binary outcome: one-stage or two-stage? *PLoS One* 2013;8(4):e60650.

31. Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Statistics in Medicine* 2002;21(11):1539-1558.

32. Keil T, Bockelbrink A, Reich A, Hoffmann U, Kamin W, Forster J, et al. The natural history of allergic rhinitis in childhood. *Pediatric Allergy and Immunology* 2010;21(6):962-969.

33. Kurukulaaratchy RJ, Matthews S, Arshad SH. Defining childhood atopic phenotypes to investigate the association of atopic sensitization with allergic disease. *Allergy* 2005;60(10):1280-1286.

34. Kurukulaaratchy RJ, Karmaus W, Raza A, Matthews S, Roberts G, Arshad SH. The influence of gender and atopy on the natural history of rhinitis in the first 18 years of life. *Clinical & Experimental Allergy* 2011;41(6):851-859.

35. Chawes BLK, Kreiner-Møller E, Bisgaard H. Objective assessments of allergic and nonallergic rhinitis in young children. *Allergy* 2009;64(10):1547-1553.

36. Vink NM, Postma DS, Schouten JP, Rosmalen JG, Boezen HM. Gender differences in asthma development and remission during transition through puberty: the TRacking Adolescents' Individual Lives Survey (TRAILS) study. *J Allergy Clin Immunol* 2010;126(3):498-504 e491-496.

37. Pinart M, Benet M, Annesi-Maesano I, von Berg A, Berdel D, Carlsen KCL, et al. Comorbidity of eczema, rhinitis, and asthma in IgE-sensitised and non-IgE-sensitised children in MeDALL: a population-based cohort study. *The Lancet Respiratory Medicine* 2014;2(2):131-140.

38. Gough H, Grabenhenrich L, Reich A, Eckers N, Nitsche O, Schramm D, et al. Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. *Pediatr Allergy Immunol* 2015;26(5):431-437.

39. Ballardini N, Kull I, Lind T, Hallner E, Almqvist C, Ostblom E, et al. Development and comorbidity of eczema, asthma and rhinitis to age 12: data from the BAMSE birth cohort. *Allergy* 2012;67(6):537-544.

40. Moyes CD, Clayton T, Pearce N, Asher MI, Ellwood P, Mackay R, et al. Time trends and risk factors for rhinoconjunctivitis in New Zealand children: an International Study of Asthma and Allergies in Childhood (ISAAC) survey. *J Paediatr Child Health* 2012;48(10):913-920.

41. Fagan JK, Scheff PA, Hryhorczuk D, Ramakrishnan V, Ross M, Persky V. Prevalence of asthma and other allergic diseases in an adolescent population: association with gender and race. *Ann Allergy Asthma Immunol* 2001;86(2):177-184.

42. Becklake MR, Kauffmann F. Gender differences in airway behaviour over the human life span. *Thorax* 1999;54(12):1119-1138.

43. Uekert SJ, Akan G, Evans MD, Li Z, Roberg K, Tisler C, et al. Sex-related differences in immune development and the expression of atopy in early childhood. *J Allergy Clin Immunol* 2006;118(6):1375-1381.

44. Osman M. Therapeutic implications of sex differences in asthma and atopy. *Arch Dis Child* 2003;88(7):587-590.

This article is protected by copyright. All rights reserved.
### Table 1  Baseline characteristics and presence of puberty by age for each birth cohort and pooled

| Table | Baseline characteristics and presence of puberty by age for each birth cohort and pooled |
|-------|--------------------------------------------------------------------------------------|
| **PIAMA (n=3963)** | | |
| M | F | M | F | M | F | M | F | M | F | M | F |
| n/N | n/N | n/N | n/N | n/N | n/N | n/N | n/N | n/N | n/N | n/N | n/N |
| **BAMSE (n=4089)** | | | | | | | | | | | | |
| **GINIplus (n=5991)** | | | | | | | | | | | | |
| **LISAplus (n=3094)** | | | | | | | | | | | | |
| **DARC (n=562)** | | | | | | | | | | | | |
| **MAS (n=1314)** | | | | | | | | | | | | |
| **Total** | | | | | | | | | | | | |
| **Sex** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Parental allergy** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Maternal smoking during pregnancy** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 10** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 11** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 12** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 13** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 14** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 15** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |
| **Puberty at age 16** | | | | | | | | | | | | |
| n | N | M | F | M | F | M | F | M | F | M | F |

M: Male, F: Female.
Table 2  Adjusted odds ratios* with 95%-confidence intervals (CI) for sex-effect (female vs male) before and after puberty for two-stage meta-analysis incl. assessment of heterogeneity among the cohorts using $I^2$

| Outcome                                      | Two stage IPD Meta-analysis | Heterogeneity $I^2$ | Before puberty onset | After puberty onset |
|----------------------------------------------|-----------------------------|---------------------|----------------------|---------------------|
| Current rhinitis only                        | 0.78                        | $I^2=0\%$           | 0.72-0.84            | 0.90                |
|                                              |                             |                     | (0.80-1.02)          |                     |
| Current asthma only                         | 0.71                        | $I^2=0\%$           | 0.62-0.82            | 0.82                |
|                                              |                             |                     | (0.64-1.06)          |                     |
| Current allergic multimorbidity              | 0.54                        | $I^2=11\%$          | 0.46-0.65            | 0.85                |
|                                              |                             |                     | (0.71-1.03)          |                     |
| IgE associated current rhinitis only (without asthma) | 0.66                        | $I^2=54.9\%$        | 0.52-0.84            | 0.75                |
|                                              |                             |                     | (0.66-0.86)          |                     |
| IgE associated current asthma only (without rhinitis) | 0.53**                      | $I^2=2\%$           | 0.40-0.70            | 0.62**              |
|                                              |                             |                     | (0.42-0.91)          |                     |
| IgE associated current allergic multimorbidity | 0.52                        | $I^2=0\%$           | 0.42-0.66            | 0.84                |
|                                              |                             |                     | (0.68-1.05)          |                     |
| Non-IgE associated current rhinitis only (without asthma) | 0.94                        | $I^2=0\%$           | 0.83-1.06            | 1.17                |
|                                              |                             |                     | (1.02-1.34)          |                     |
| Non-IgE associated current asthma only (without rhinitis) | 0.84**                      | $I^2=0\%$           | 0.69-1.03            | 1.17**              |
|                                              |                             |                     | (0.81-1.72)          |                     |
| Non-IgE associated current allergic multimorbidity | 0.73**                      | $I^2=57.8\%$        | 0.42-1.27            | 0.97**              |
|                                              |                             |                     | (0.53-1.79)          |                     |

* adjusted for age, parental allergy and maternal smoking during pregnancy
** due to small prevalence in some cohorts not including all cohort estimators
FIGURE LEGENDS

Figure 1 Sex specific prevalence with 95%-CI of current rhinitis only (on a logarithmic scale) in six European birth cohorts by age

Figure 2 Sex specific prevalence with 95%-CI of current asthma only (on a logarithmic scale) in six European birth cohorts by age

Figure 3 Sex specific prevalence with 95%-CI of current allergic multimorbidity (on a logarithmic scale) in six European birth cohorts by age

Figure 4 Odds Ratios from one stage IPD meta-analysis of sex effect (female vs male) before and after puberty for all outcomes

LEGENDS IN THE SUPPLEMENT

Table S1 Overview of included follow-up assessments of included birth cohort studies and available exposure/outcome data

Table S2 Sex-specific prevalence of current rhinitis only in six European birth cohorts by age

Table S3 Sex-specific prevalence of current asthma only in six European birth cohorts by age

Table S4 Sex-specific prevalence of current allergic multimorbidity (asthma and concurrent rhinitis) in six European birth cohorts by age

Table S5 Sensitivity analyses: Odds ratios for the primary outcomes from one stage IPD meta-analyses of sex effect (female vs male) before puberty and in subjects with early or late onset of puberty

Table S6 Sensitivity analyses including IgE against food allergens for definition of allergic sensitization status: Adjusted odds ratios* with 95%-confidence intervals (CI) for sex-effect (female vs male) before and after puberty for one-stage meta-analysis
Figure 1 Sex specific prevalence of current rhinitis only (on a logarithmic scale) in six European birth cohorts by age.
Figure 2 Sex specific prevalence of current asthma only (on a logarithmic scale) in six European birth cohorts by age
Figure 3 Sex specific prevalence of current allergic multimorbidity (on a logarithmic scale) in six European birth cohorts by age.
| Outcome                                      | Odds Ratio OR 95% CI | Sex*puberty interaction p-value |
|----------------------------------------------|----------------------|---------------------------------|
| Current rhinitis only (n = 14323)            |                      |                                 |
| Before puberty                               | 0.79 [0.73:0.86]     | 0.089                           |
| After puberty                                | 0.88 [0.79:0.94]     |                                 |
| Current asthma only (n = 14323)              |                      |                                 |
| Before puberty                               | 0.71 [0.63:0.81]     | 0.327                           |
| After puberty                                | 0.81 [0.74:1.02]     |                                 |
| Current allergic multimorbidity (n = 14323)   |                      |                                 |
| Before puberty                               | 0.55 [0.45:0.66]     | <0.001                          |
| After puberty                                | 0.69 [0.60:0.80]     |                                 |
| Eye allergic current rhinitis only (n = 11971) |                      |                                 |
| Before puberty                               | 0.89 [0.80:0.98]     | 0.279                           |
| After puberty                                | 0.70 [0.67:0.74]     |                                 |
| Eye allergic current asthma only (n = 11971)  |                      |                                 |
| Before puberty                               | 0.56 [0.42:0.74]     | 0.329                           |
| After puberty                                | 0.68 [0.46:0.99]     |                                 |
| Eye allergic current allergic multimorbidity (n = 11971) |          |                                 |
| Before puberty                               | 0.55 [0.44:0.71]     | <0.001                          |
| After puberty                                | 0.91 [0.73:1.13]     |                                 |
| Non-eye associated current rhinitis only (n = 10872) |          |                                 |
| Before puberty                               | 0.99 [0.87:1.12]     | 0.085                           |
| After puberty                                | 1.13 [1.00:1.29]     |                                 |
| Non-eye associated current asthma only (n = 10872) |          |                                 |
| Before puberty                               | 0.81 [0.76:0.87]     | 0.164                           |
| After puberty                                | 0.97 [0.76:1.24]     |                                 |
| Non-eye associated current allergic multimorbidity (n = 10872) |          |                                 |
| Before puberty                               | 0.53 [0.47:0.60]     | 0.020                           |
| After puberty                                | 1.04 [0.71:1.53]     |                                 |

Figure 4 Odds Ratios from one stage IPD meta-analysis of sex effect (female vs male) before and after puberty for all outcomes.